Status:
COMPLETED
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
Lead Sponsor:
Eli Lilly and Company
Conditions:
Overweight
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests w...
Eligibility Criteria
Inclusion
- Are native Chinese males or females
- Have had a stable body weight for the 3 months prior to randomization (less than 5% body weight change) and body mass index of ≥ 30.0 kilograms per square meter (kg/m²) or between 27.0 up to 30.0 kg/m² with at least 1 of the following weight-related comorbidities including Hypertension, Dyslipidemia, Cardiovascular disease, Obstructive sleep apnea
Exclusion
- Have any prior diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus
- Have used or intend to use any prescription or over-the-counter medications or traditional Chinese treatments within 3 months prior to screening, exception of medications for the treatment of concurrent medical conditions with a stable dose
- Have known allergies to GLP-1RAs, LY3502970, related compounds, any components of the formulation, or have a history of significant atopy
- Are overweight or have obesity induced by other endocrinological disorders, diagnosed monogenetic, or syndromic forms of obesity
- Have or plan to have a surgical, endoscopic or device-based treatment for obesity
- Have a history or presence of psychiatric disorder, a moderately severe or severe depression status, or a significantly risk for suicide
- Have a history of acute or chronic pancreatitis
- Have a known self or family history of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma
- Have other acute, chronic, or uncontrolled medical conditions, vital organ failure or abnormal laboratory value in the judgment of the investigator would make the participant inappropriate for entry into this study
Key Trial Info
Start Date :
September 21 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 29 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06023095
Start Date
September 21 2023
End Date
July 29 2024
Last Update
August 27 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
2
West China Hospital Sichuan University
Chengdu, Sichuan, China, 610041
3
Shanghai General Hospital
Shanghai, Songjiang, China, 201620